Johann Foloppe, et al.
Molecular Therapy Oncolytics, March 2019 – Download the article
Publication
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Par Lucie Larguier|2019-07-01T12:14:26+02:00mars 27th, 2019|Publication, TG6002|Commentaires fermés sur The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
À propos de l'auteur : Lucie Larguier
Articles similaires
- TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity